Drug Profile
Research programme: lipocalin derived cancer immunotherapeutics - Pieris Pharmaceuticals/ Roche
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Pieris
- Developer Pieris Pharmaceuticals; Roche
- Class Antineoplastics; Lipocalins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer